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ABSTRACT 
Zinc deficiency during pregnancy has been related to adverse pregnancy outcomes. However, the results 
of zinc-supplementation trials have not been consistent in improvement of pregnancies outcomes. This 
study was undertaken to investigate whether zinc supplementation was associated with pregnancy 
complications in Iranian women during the last 2 trimesters. It also assessed the anthropometric 
measurements of infants at birth. A double-blind placebo-controlled trial was conducted in Ardabil 
Province located in northwest of Iran. One-hundred ninty-six pregnant women between 16-20 weeks of 
gestation were recruited from urban healthcare centres. These women had no evidence of hypertension, 
diabetes, renal disease, history of prematurity, premature rupture of membranes (PROM) or low birth 
weight (LBW) infants. They were randomly assigned to receive zinc (50 mg daily) or placebo until 
delivery. Basic information was collected on socioeconomic status, reproductive and disease histories 
before randomization. The subjects were monthly followed during pregnancy and maternal complications 
were carefully recorded. The weight, length and head circumference of each infant was measured within 
24h of birth. Of the 196 women, 17 were excluded from the study (9 in the zinc group and 8 in the 
placebo group, NS). The supplementation had no significant effect on prematurity, preeclampcia, PROM 
and stillbirth as well as gestational age, infant length and head circumference. The incidence of low birth 
weight was significantly lower in those under Zinc than placebo (p = 0.01). Meanwhile, pregnancy-
induced hypertension and intrauterine growth retardation (IUGR) were observed only in the placebo 
group. The birth weight was also higher in the zinc group than that in the placebo group (p = 0.03). 
Supplementation with 50mg elemental zinc during pregnancy improved birth weight but did not reduce 
maternal complications. 
Keywords: Zinc supplementation, Pregnancy outcome, Maternal complications  
Zinc has received increasing attention since its 
deficiency may have grave consequences in humans [ 1, 
 2]. Zinc is an essential component of various enzymes 
and other proteins including bio-membrane components. 
It is necessary to maintain the normal structure and/or 
function of many enzymes, including some involved in 
gene transcription and translation and cell division [ 3]. 
The physiological role of zinc during periods of rapid 
growth and development emphasizes its importance 
during periods of gestation and fetal growth [ 4]. 
Maternal nutritional status is an important 
determinant of prenatal and neonatal well-being. Many 
nutritional programs have been established to prevent 
iron-deficiency anaemia during pregnancy. However, in 
the case of zinc, less has been done, although it is very 
important for maternal and infant survival. It was 
reported that 82% of pregnant women worldwide have 
an irregular and inadequate zinc intake. However, 
reports are inconsistent regarding association of 
maternal zinc status and birth weight in humans [ 5]. 
Recently, maternal zinc supplementation has been 
suggested as a possible nutritional intervention to 
improve the outcomes of pregnancies in developing 
countries [ 6]. Goldenberg et al. [ 7] found that 25mg of 
daily zinc supplementation in early pregnancy was 
related to greater infant birth weight and head 
circumference. Women who received 25mg zinc daily 
from the day of reporting pregnancy showed significant 
increases in serum zinc until delivery. In addition, their 
babies had higher birth weights and gestational ages 
than subjects under placebo [ 7]. Most of the studies 
about the effects of zinc supplementation on pregnancy  
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Table 1. Maternal baseline characteristics 
 Zinc supplemented group Placebo group 
Age at enrolment 24.5 ± 4.8 23.9 ± 5.2 
Parity 1.5 ± 0.8 1.6 ± 0.9 
Education (yr) 7.7 8.2 
Job housewife (%) 85 (95.6%) 84 (93.3%) 
Weight (kg)  61.9 ± 8.9 63.5 ± 10.4 
Height (cm) 160.2 ± 8.1 158.8 ± 6.1 
BMI (kg/m2) 24.1 ± 3.9 25.3 ± 4.0 
 
outcome have been carried in industrialized countries 
and results have been inconclusive [ 8]. However, 
women from developing countries are more likely to be 
zinc deficient; therefore, they may be at higher risk of 
producing low birth weight infants. Despite these risks, 
few data are available from developing countries in this 
regard. In a review published in 2003, Osendarp et al. 
[ 6] discussed preliminary findings from eight recent 
randomized controlled intervention trials in less-
developed countries. These findings indicated that 
maternal zinc supplementation has a beneficial effect on 
neonatal immune status, early neonatal morbidity and 
infant infections; with respect to labour and delivery 
complications, gestational age at birth, maternal zinc 
status and health, and neurobehavioral development of 
the foetus. However, these findings are conflicting and 
more researches are required [ 6]. The results of a 
national survey in Iran showed low plasma zinc is 
prevalent among pregnant women [ 9]. Zinc intake was 
shown to be low among women in both urban and rural 
areas [ 10]. We performed a double-blind, placebo-
controlled zinc-intervention trial among pregnant 
women to find whether zinc supplementation can reduce 
risk of delivering low birth weight infants or not.  
PATIENTS AND METHODS 
A total of 196 pregnant women living in urban areas 
of Ardabil district located in North-west of Iran were 
recruited between April 2004 and March 2005. The 
final sample size required to enable detection of 
difference of 310 gram in birth weight, with 80% power 
and a type 1 error of 5%, assuming a S1=700 and 
S2=600 was calculated 92 in each group. They were 
identified while they were between 16 and 20 wk of 
gestation. Gestational age on enrolment was determined 
by the date of last menstrual period (LMP) as recalled 
by the women. The subjects were randomly selected 
from their health records kept in Ardabil's health care 
centers. (There are 14 urban health care centres in 
Ardabil city; we selected women from each centre). 
They were all resident in Ardabil, had no histories of 
diabetes, hypertension or renal disease, and provided 
informed consent. The study was approved by the 
Ethics Committee and Research Council of Ardabil 
University of Medical Sciences. 
The study was double-blind and the women were 
randomly assigned to receive either 50 mg daily 
elemental zinc as zinc sulphate (n=98), or placebo 
(n=98). Basic information was collected on 
socioeconomic status, reproductive and disease history 
of each participant before beginning supplementation. 
The zinc sulphate and placebo capsules were made 
by the Alhavi Company. The placebo capsules were 
similar to the zinc sulphate capsules in both shape and 
blister packing. The zinc sulphate was coded as "A” and 
the placebo as "B", however, both interviewers and 
participants remained blind of these codes until the 
study was completed. The women were followed during 
study until delivery. In addition to the zinc, all subjects 
received 1mg folic acid and 30mg ferrous sulphate 
tablets (Iron and folic acid at night, zinc sulphate or 
placebo at midmorning). Anthropometric 
measurements, blood pressure and information on 
compliance were assessed and recorded monthly by 
trained midwives working in each centre. Those with 
complications or other problems were referred to a 
gynaecologist who was co-investigator in the project. 
She was also blind to the subject allocation. Gestational 
age assessment, birth-weight and infant anthropometric 
measurements were performed by trained midwives 
within 24h of birth. In this study, low birth weight 
(LBW) was defined as body weight at birth of less than 
2500g, preterm birth was defined those infants delivered 
prior to the completion of 37 weeks, intrauterine growth 
retardation (IUGR) defined as an infant whose birth 
weight is usually below 10th percentile for its 
gestational age [ 11]. 
Main delivery outcome variables were compared 
between trial and placebo group using chi-square, 
Fishers’ exact test or ANOVA using SPSS 14 for 
Windows. The RR was calculated using EPI Info 2002. 
RESULTS 
A total of 196 subjects were recruited and randomly 
assigned in two groups. Six refused to participate (3 in 
zinc and 3 in placebo group), remaining (190) were 
included in the study. Subjects who consumed placebo 
or supplement irregularly (on fewer than 21 days per 
month or 70% compliance) were excluded; 11 (5.8%) 
were excluded (6.3% in the zinc group and 5.3% in 
placebo group NS), they withdrew prior to the outcome 
being measured, but 93.2% of the participants 
consumed Zinc supplement or placebo regularly (Fig. 
1). Duration of supplementation was 20.2 ± 2.6 weeks 
in zinc group and 20.5 ± 2 weeks in placebo group. 
Both groups had similar maternal baseline 
characteristics (Table 1) and they were not different in 
socioeconomic status.  Anthropometric measurements 
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Table 2. Infant characteristics by type of prenatal supplement consumed during pregnancy   
 Mean ± SD 95% CI 
Gestational age (week) 
Supplemented(n=87)  
Placebo(n=88) 
Birth weight (kg) 
 
38.3 ± 1.8 
38.2 ± 2.9 
 
37.9 - 38.7 






Head circumference (cm) 
Supplemented(n=87)  
Placebo(n=88) 
Low birth weight (<2500 g) 
Supplemented(n=87)  
Placebo(n=88) 
3513 ± 400 
3352 ± 544 
 
49.7 ± 1.5 
50.2 ± 3.2 
 
35.7 ± 2.7 




3427 - 3599 
3238 - 3467 
 
49.4 - 50 
49.5 -50.9 
 
35.2 - 35.8 





Table 3. Maternal complications 
 Zinc group (n=89) Placebo group (n=90) RR (95% CI) 
PROM 6 (6.7%) 6 (6.6%) 1.12 (0.38 - 3.36) 
Preeclampcia & Eclampcia 3 (3.4%) 5 (5.6%) 0.61 (0.15 - 2.46) 
Hypertension 0 (0.0%) 2 (2.2%) - 
Preterm delivery  9 (9.3%) 7 (7.8%) 1.30 (0.51 - 3.34) 
Still birth  2 (2.3%) 2 (2.2%) 1.01 (0.15 - 7.20) 
    
were compared within two groups of supplemented and 
placebo (Table 2). There was a significant difference in 
average birth weight between the zinc and the placebo 
groups (p=0.03). LBW infants were seen in women 
taking Zinc supplement, while six women in placebo 
group had LBW infants (p = 0.01). Two of six LBW 
infants were IUGR. All infants delivered prematurely 
were of >2500 g in the zinc group by exception of one 
infant who had died in the 28 wk of gestational age. 
However, the treatment did not significantly affect 
infant length, head circumference or gestational age at 
birth. 
The average weight gain between the time of 
enrolment (usually 4-8 wk of pregnancy) and end of 
pregnancy was not significantly different between two 
groups (10.1 ± 4.03 in the zinc group and 10.3 ± 3.9 in 
the placebo group). Of the 179 women who completed 
the follow-up until delivery, 4 (2 in the zinc-
supplemented and 2 in the placebo group, NS) delivered 
a stillborn fetus or an infant that died shortly after birth. 
Maternal complications were not different between the 
two groups (Table 3). 
None of women taking zinc delivered infants with 
IUGR, whereas 2 subjects (2.2%) in the placebo group 
delivered infants with IUGR. Pregnancy-induced 
hypertension was also observed only in the placebo 
group (2.2%). 
DISCUSSION 
In this study, Infants born from mother under zinc 
supplementation had birth weights of 3513 ± 400 gram 
compared to 3352 ± 544 gram in the placebo group 
(p=0.03). None of women taking zinc delivered low 
birth weight infants. Zinc supplementation had no 
significant effect on neonatal head circumference and 
length. Zinc treatment also had no significant effect on 
gestational age or maternal complications. However, 
some complications (pregnancy-induced hypertension 
and IUGR) were observed only in those under placebo.  
Castillo-Duran et al. [ 12] analyzed the effect of zinc 
supplementation on pregnancy outcomes among 
Chilean adolescents of low socioeconomic status. They 
found significantly higher birth weights, fewer infants 
with low birth weight and a lower rate of prematurity in 
the Zinc group compared to the placebo group, although 
they did not report any effects on pregnancy 
complications. In a study conducted in India by Garg et 
al. [ 13], Zinc supplements significantly improved foetal 
growth. The effect on birth weight was greater 
whenever the supplement initiated in the first trimester, 
than in the third trimester [ 13]. Goldenberg et al. [ 5] 
studied the effect of Zinc supplements on birth weight 
in a group of medically indigent African-American 
women. Women at risk of poor zinc nutrition were 
targeted for this intervention study. The supplement had 
a significant effect on increasing birth weight and head 
circumference only in non-obese women (BMI<26). 
Some investigators have observed a significant 
reduction in preterm deliveries in Zinc-supplemented 
pregnant women [ 5, 13, 14]. This effect was only 
observed among normal-weight women in the group 
studied by Cherry et al. [ 14]. Among Indian women, the 
gestational age of the infant increased more with longer 
periods of Zinc supplementation; those who received 
the supplement from the first trimester had an average 
gestational age of 39.4 wk, while those supplemented 
only from the third trimester had a gestational age of 
38.8 wk. The average gestational age among the placebo 
group was 38.3 weeks [ 13]. Goldenberg et al. [ 5]  
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Fig 1. Flowchart of study 
196 women randomized 
98 assigned to receive 50mg zinc as assigned 
3 refusals to participation 
98 assigned to receive placebo as assigned 
3 refusals to participation 
89 completed study treatment 
6 discontinued study consumption fewer than<21 days per 
month and withdrew prior to the outcome being measured 
90 completed study treatment 
5 discontinued study, consumption fewer than<21 days per 
month and withdrew prior to the outcome being measured 
89 included in analysis 90 included in analysis 
reported a tendency toward increased gestational age 
(p<0.08) among women with BMI <26.  
Simmer et al. [ 15] studied mothers at risk of 
delivering infants with intrauterine growth retardation 
and reported reduced IUGR in 29 compliers.  Hunt et al. 
[ 16] found that 20 mg daily Zinc supplements reduced 
the incidence of pregnancy-induced hypertension 
among adult Hispanic women but not among adolescent 
Hispanic women. These findings are in contrast with 
some studies in which no effect of zinc interventions on 
pregnancy outcomes was found [ 17- 23]. 
Supplementation with 50 mg elemental zinc during 
pregnancy improved birth weight but did not affect 
maternal complications. The results of the study are 
consistent with those obtained from zinc 
supplementation trials conducted on pregnant women in 
other parts of the world. This may suggest beneficial 
effect of maternal zinc supplementation on size at birth. 
This controversy could be explained by three possible 
reasons. Firstly, a higher dose of zinc was given in this 
study (50 mg) which may affect fetal growth. Caulfeild 
et al. [ 18] used 15 mg supplementation. In the other 
study in which no difference was found, 30 mg of zinc 
was given [ 17]. Secondly, our subjects had higher BMI 
(24.7) compared to other in which no difference was 
seen [ 17]. The higher BMI would likely favour higher 
average birth weight. Thirdly, it may be true that in 
some populations, improvements in maternal zinc 
nutriture mostly occur before pregnancy or early in 
pregnancy to affect pregnancy. More evidence on this is 
required in other developing countries. 
This study has several strengths that lend credence 
to the findings. First, compliance with supplementation 
was high. Second, the randomization of the women to 
prenatal supplement type formed comparable treatment 
groups at enrolment. Third, the outcomes were 
measured reliably, and all maternal complications were 
confirmed by a gynaecologist. Fourth, the loss to 
follow-up was minimal.  Fifth, zinc supplementation 
was initiated between 16 and 20 weeks of pregnancy in 
all cases.  The most important limitation of this study 
was the exclusion of women who took less than 70% 
compliance because they withdrew prior to the outcome. 
CONCLUSION 
This randomized double-blind study suggests that 
zinc supplements may improve infants' birth weight. 
Although, this finding needs to be confirmed in further 
studies with larger sample size, optimal micronutrient 
could be encouraged. 
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